MedTrace Logo

Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

NCT01917110 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2020-08-03

No results posted yet for this study

Summary

The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.

Conditions

  • Myopia

Interventions

DEVICE

omafilcon A

DEVICE

Spectacle

Sponsors & Collaborators

  • CooperVision, Inc.

    lead INDUSTRY

Principal Investigators

  • Cesar Villa Collar, OD PhD FAAO · Departamento de Optica y Optometria de la Universidad Europea de Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-13
Primary Completion
2016-06-16
Completion
2016-06-16

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01917110 on ClinicalTrials.gov